双重修饰的反意义寡核酸向致癌原核素治疗胃癌
Mitsuro Kanda1, Yuuya Kasahara2, Dai Shimizu3
1Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. m-kanda@med.nagoya-u.ac.jp.
新型的反感性寡核酸向protocadherin alpha 11 (PCDHA11) 有效地抑制胃癌细胞的增殖和转移. 这种针对PCDHA11的策略显示出治疗胃癌和其他固体瘤的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 胃癌是一个重大的全球健康挑战.
- 甲基11 (PCDHA11) 已与癌细胞增殖有关.
- 针对特定的基因提供了潜在的治疗途径.
研究的目的:
- 开发和评估针对PCDHA11的反感性寡核酸 (ASOs) 用于胃癌治疗.
- 研究PCDHA11在胃癌进展中的作用.
- 评估新型氨基酸桥接核酸 (AmNA) 修改ASOs的疗效和安全性.
主要方法:
- 设计并选了54个AmNA修饰的ASO用于PCDHA11敲击.
- 评估ASO对胃癌细胞功能和信号通路 (AKT/mTOR,Wnt/β-catenin,JAK/STAT) 的影响.
- 在胃癌转移和瘤生长的小鼠模型中评估ASO疗效.
主要成果:
- 用AmNA修饰的抗PCDHA11 ASO显著降低了胃癌细胞的扩散和转移.
- 过度表达PCDHA11与增强的细胞增殖有关.
- 在体内,ASO治疗抑制了瘤的生长,但导致可逆性肝损伤.
结论:
- 用AmNA修饰的抗PCDHA11 ASO代表了胃癌的有前途的治疗策略.
- 这种方法也可能对其他固体恶性瘤有效.
- 需要进一步的研究来优化ASO治疗和减轻副作用.
更多相关视频
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Inhibition of Cdk Activity
